Conception
Sílvia Llonch Armengol, PhD, is currently working as a Senior Scientist at Conception since March 2023. Prior to this role, they worked as a Scientist at the same company from March 2022 to March 2023.
From April 2019 to February 2022, Sílvia worked as a Research Scientist at the Centre for Genomic Regulation (CRG).
Before joining CRG, they served as an Early Stage Researcher at Technische Universität Dresden (Center for Regenerative Therapies Dresden, CRTD) from October 2014 to February 2019.
In 2013, Sílvia worked as a Researcher for their Master's project at Clínica Eugin, collaborating between the Tissue Engineering lab in IQS and the R&D department in Clínica Eugin. Sílvia also assisted in establishing the R&D lab during this time.
Additionally, they worked as a Teaching Assistant at IQS Barcelona from February to June 2014.
Prior to their Master's project, Sílvia had a student role at Parc Científic de Barcelona in July to September 2012 and at Universitat Autònoma de Barcelona from July 2011 to January 2012.
Sílvia Llonch Armengol, PhD, completed their education in a chronological order. Sílvia started their academic journey in 2008 at Universitat Autònoma de Barcelona, where they obtained a Licentiate degree in Biotechnology in 2012. Following this, from 2012 to 2014, they attended IQS Barcelona and earned a Master's degree in Bioengineering. Sílvia then pursued their Doctor of Philosophy (PhD) at Technische Universität Dresden from 2014 to 2018, specializing in Regenerative Medicine. In addition to their formal education, they also acquired a Certificate in Advanced English from the University of Cambridge in March 2010.
Conception
Conception is a company developing the technology to turn skin cells into viable human eggs.This technology will give women the opportunity to have children well into their forties and fifties, eliminate barriers for couples suffering from infertility, and potentially allow male-male couples to have biological children.Long term, thistechnology could be a critical platform allowing for widespread genetic screening of embryos. If proven safe, it could even enable for genetic editing to eliminate and reduce the risk of devastating diseases for future generations – such as Alzheimer’s, heart disease and many different types of cancers.This could become one of the most important technologies ever created.The company was founded in 2018 and is headquartered in Berkeley, California.